ARA-290 peptide: what it is and what research shows in 2026

ARA-290, also called cibinetide, is a lab-made peptide built from a small piece of erythropoietin (EPO). Unlike EPO, it does not raise red blood cells. Instead it is thought to switch on the body's "innate repair receptor," which is being studied for calming inflammation and helping damaged nerves heal.

Most human research so far looks at small fiber neuropathy in people with sarcoidosis. It is still investigational and not approved anywhere. Looking into how you recover is a smart, proactive instinct, and this guide gives you the grounded version.

What is the ARA-290 peptide?

ARA-290 is a synthetic 11-amino-acid peptide, also known as cibinetide or the "helix-B surface peptide." It is copied from a small part of erythropoietin (EPO), the natural hormone that tells your body to make red blood cells. Scientists redesigned that fragment to keep EPO's tissue-protective, anti-inflammatory side while removing its red-blood-cell effect. So ARA-290 is studied for repair and inflammation, not for boosting blood counts.

• Type: lab-made peptide, 11 amino acids, derived from EPO
• Also called: cibinetide, ARA 290, helix-B surface peptide
• Studied for: small fiber neuropathy, nerve pain, tissue repair, inflammation
• Status: investigational; holds FDA orphan-drug and fast-track designations for sarcoidosis nerve pain, but is not approved for sale

How does ARA-290 work?

ARA-290 is thought to work by switching on the innate repair receptor, or IRR. Here is the simple version. When tissue is injured, cells build a special receptor made of the EPO receptor joined to a second piece called CD131 (the beta common receptor). This IRR only shows up around injury. ARA-290 is designed to fit that receptor and turn on the body's own repair and anti-inflammation program, without touching the separate receptor that makes red blood cells.

• Targets the innate repair receptor (EPO receptor + CD131), which appears mainly in injured tissue
• Is thought to reduce inflammation and slow cell death in that area
• May also calm the TRPV1 channel on small nerve fibers, which is tied to pain signaling
• Does not stimulate red blood cell production, unlike EPO itself

Because the repair receptor mostly appears where there is damage, researchers describe ARA-290 as acting where it is needed rather than across the whole body. This idea is still being studied in humans and animals.

ARA-290 and neuropathy: what is the connection?

Neuropathy is nerve damage that often causes pain, burning, or numbness, usually in the hands and feet. Small fiber neuropathy affects the tiny nerve endings in the skin. ARA-290 has been studied most for this exact problem, especially in people with sarcoidosis, an inflammatory disease that can damage small nerves. The idea is that ARA-290 may lower inflammation around those nerves and support the fibers as they recover.

In a placebo-controlled pilot study of 22 sarcoidosis patients, people given ARA-290 (2 mg, three times a week for 4 weeks) reported better nerve-symptom scores and improvements in pain and physical function versus placebo. A follow-up study reported an increase in corneal nerve fiber density, a way to measure small nerve fibers in the eye. Diabetic-neuropathy research is also underway.

What does the research on ARA-290 show?

Most ARA-290 evidence comes from human trials and animal studies, mainly around nerve damage and inflammation. Here is a summary of the main findings.

ARA-290 was developed by Araim Pharmaceuticals and earned FDA orphan-drug and fast-track status for sarcoidosis-related nerve pain. That status flags an unmet need; it is not approval. As of 2026 there is no marketed ARA-290 product and no active late-stage US trial that has reported approval.

What are ARA-290's potential benefits?

Based on research so far, ARA-290 is studied for a short list of related effects. It is not approved, and most human data comes from sarcoidosis nerve pain.

• Support for small nerve fibers and possible relief of nerve pain
• Lower inflammation around injured tissue
• General tissue protection during healing
• A repair-focused action that does not raise red blood cells

For most active people focused on recovery, ARA-290 is a research topic rather than an option today. Better-studied recovery peptides and copper peptides are covered in our best peptides for injury recovery and copper peptides guides.

How is ARA-290 used in research?

In studies, ARA-290 has been given as an injection, often under the skin or into a vein, in the range of about 2 to 4 mg per dose. Trial schedules varied, such as a few times a week for several weeks. These are research protocols run under medical supervision, not consumer instructions. There is no approved, standardized ARA-290 dose because it is not an approved product.

Is ARA-290 safe? What are the side effects?

In the small trials done so far, ARA-290 was generally well tolerated, and researchers did not flag major safety concerns on clinical or lab checks. A helpful design feature is that it is built to skip EPO's red-blood-cell effect, which is the part of EPO tied to clotting and cardiovascular risk. Still, the safety record is based on small, short studies, so long-term effects in the general public are simply unknown.

• Reported as well tolerated in small, short trials
• Designed to avoid EPO's red-blood-cell and clotting effects
• Long-term safety in healthy adults is not established
• Injection-site reactions are possible with any injectable peptide

Where to buy ARA-290 and why the grey market is risky

Here is the direct answer to "where can I buy ARA-290?" Today ARA-290 is sold almost entirely as research-grade or grey-market vials, usually labeled "not for human use." That path has no prescriber checking whether it is right for you, no licensed pharmacy standing behind the product, and no way to verify what is actually in the vial. Purity, dose accuracy, and sterility are all unverified.

A safer model puts a licensed physician and a regulated pharmacy in the loop for any peptide you take. That is exactly how pru is built.

How pru handles peptides like ARA-290

pru is a telehealth platform for peptides done the right way. You choose the therapy you are interested in, a licensed physician confirms whether it fits you, and an FDA-regulated 503A pharmacy compounds and fills it. Membership is about $50 a month, and peptides are billed separately at cost, itemized, with no markup on the medicine.

• A licensed physician confirms fit; you are never self-prescribing from a vial
• Compounding is done by an FDA-regulated 503A pharmacy, not a grey-market seller
• Peptides are priced at cost and itemized, separate from the flat membership
• You select the therapy; the physician confirms it is appropriate

ARA-290 itself is still investigational, so it is a research topic here rather than a product. In the same recovery and repair space, pru's GHK-Cu copper peptide cream is live today. Two better-known repair peptides, BPC-157 and TB-500, were removed from the FDA's 503A Category 2 list in April 2026 and go before the Pharmacy Compounding Advisory Committee on July 23-24, 2026. pru is preparing to offer them the right way, physician-prescribed and 503A-compounded, if and when that pathway opens.

If you are ready to be proactive about recovery today, pru exists to make the informed choice the accessible one: licensed physicians, pharmacy-grade medicine, and at-cost pricing in one place. See the full repair and regeneration catalog or how membership works.

Related reading

• Best peptides for injury recovery
• Best peptides for tendon repair
• Thymosin beta-4 guide
• Copper peptides explained
• BPC-157 and TB-500 stack
• Peptides for gut health

Ready to see what pru offers today? Browse the GHK-Cu cream or the full shop.

Common questions